A novel series of eight thiazolidinone analogs (3a–3h) was prepared by condensing 2-(arylamino)-thiazol-4-one with pyrrole-3-carbaldehyde using glacial acetic acid as the reaction medium. Structural and physical characterization of the synthesized molecules was performed by infrared spectroscopy (IR), proton nuclear magnetic resonance (1H NMR), and mass spectrometry (MS). These techniques established the identity and purity of the derivatives prior to biological evaluation.
The synthesized compounds underwent computational evaluation to assess putative biological activity and binding interactions with the PPAR-γ receptor. Molecular docking was carried out using the human PPAR‑γ crystal structure (PDB ID: 4EMA). Docking scores identified compound 3d as having the most favorable predicted binding affinity, with a docking energy of −8.67 kcal/mol, which was reported to be better than the reference agonist rosiglitazone (−8.39 kcal/mol).
To probe complex stability and dynamic behavior, the 3d–4EMA complex was analyzed by root-mean-square deviation (RMSD) and root-mean-square fluctuation (RMSF) metrics, alongside detailed protein–ligand interaction profiling. The study additionally applied MM‑GBSA calculations to estimate binding free energy and corroborate the docking results; these analyses supported the predicted reliability of compound 3d's interaction with the receptor.
Cellular cytotoxicity of the compounds was evaluated in C2C12 myoblasts using the MTT assay to determine tolerability in a skeletal muscle cell line commonly used for metabolic studies. Following cytotoxicity assessment, the compounds were tested in a glucose uptake assay to measure functional effects relevant to antidiabetic activity.
The authors also assessed whether the compounds could modulate PPAR‑γ transcriptional activity, an important mechanism for insulin sensitivity and glucose homeostasis. Together, these in vitro assays provided both safety and mechanism-oriented functional data to support the in vivo evaluations. Specific quantitative results for cell viability, uptake levels, or transcriptional activation were not reported in the abstract.
Antidiabetic efficacy was evaluated in an established animal model: Streptozotocin-induced diabetic rats. The synthesized thiazolidinone derivatives were administered to diabetic animals and compared with a standard compound (not specified in the abstract). Compounds 3d and 3f demonstrated notable antidiabetic activity in vivo, aligning with the computational predictions that identified 3d as a lead candidate.
The study reported that treatment with these derivatives led to improvements across several biochemical markers commonly affected by diabetes. Exact experimental parameters such as dosing regimen, treatment duration, group sizes, and statistical measures were not provided in the abstract and therefore are not detailed here.
Following administration of the thiazolidinone derivatives to diabetic rats, investigators observed significant reductions in serum transaminases—SGOT and SGPT—interpreted as a potential protective effect against liver (and indirectly kidney) injury under diabetic conditions. The treated animals also exhibited decreases in multiple lipid-related parameters: HDL, LDL, VLDL, total cholesterol, and triglycerides. A reduction in serum protein was also reported.
The abstract notes histopathological assessment as part of the study scope (keyword: Histopathological), but specific histological findings, organ pathology descriptions, or representative micrographs are not summarized in the abstract and therefore are not reported here.
This work presents a thiazolidinone scaffold with promising antidiabetic properties supported by a combination of synthetic chemistry, in silico receptor engagement, in vitro functional assays, and in vivo efficacy signals. Key strengths include the identification of compound 3d as a computational and experimental lead and the use of MM‑GBSA and molecular dynamics metrics (RMSD, RMSF) to support docking reliability.
The authors conclude that the synthetic strategy enabled a novel set of derivatives that merit further optimization to improve therapeutic potential and reduce side effects. The abstract does not provide detailed toxicity profiling, pharmacokinetic data, or specific formulation and dosing strategies; these would be important next steps for preclinical development and definitive safety evaluation.
Notes on source data
All summarized findings, assay types, and comparative docking values are drawn directly from the article abstract (Biochem Biophys Res Commun. 2026; DOI: 10.1016/j.bbrc.2026.154436, PMID: 42617405). The abstract reports key outcomes but does not give numeric details for many experimental endpoints (for example, exact in vitro assay values, dosing regimens, sample sizes, or quantitative histopathology). These details were not reported in the abstract and would require consultation of the full text for complete methodological and numerical data.